PDCD1 and neoplasm: Finally, combining these antibodies with a clinical inhibitor of the PD-1/PD-L1 immune axis, Atezolizumab, resulted in an additive capacity to induce inflammatory cytokine secretion and tumor cell killing in co-culture assays.